APPLICATION NOTE

SAXS Structural Characterization of Liraglutide in Solution

Tertiary structure determination of GLP-1 analogue peptide therapeutic in pharmaceutical formulation

Method: SAXS
Sample Type: Peptide therapeutic
Application: Biopharmaceutical development

Summary

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of Type 2 diabetes mellitus and obesity. As a 31-amino acid peptide with a C16 fatty acid chain, liraglutide forms complexes in solution that affect its pharmacokinetic properties and stability.

This application note demonstrates how Small-Angle X-ray Scattering (SAXS) was employed to determine the solution structure invariants in its pharmaceutical formulation.

Background & Challenge

Clinical Importance

Liraglutide (marketed as Victoza® and Saxenda®) is a long-acting GLP-1 analogue that:

Structural Challenge

The fatty acid modification causes liraglutide to self-associate and bind to albumin, creating a complex structural behavior that:

Why SAXS? SAXS (and NMR) are the only laboratory methods capable of probing peptide structure in native solution environments without crystallization, making SAXS ideal for characterizing liraglutide as it exists in pharmaceutical formulation.

SAXS Reconstruction of PDDF Function and Radius of Gyration (Rg)

Structural Parameters

Radius of Gyration

Rg = 2.09 ± 0.2 nm

From SAXS measurement at 6 mg/mL

Formulation

6 mg/mL

Commercial formulation

Temperature

Room temperature

Pharmaceutical storage conditions

PDDF Function

Determined

Spatial distribution characterized

PDDF function of Liraglutide

Figure 1. Pair Distance Distribution Function (PDDF) of liraglutide pharmaceutical formulation (6 mg/mL) showing spatial distribution of atoms within the peptide structure. Rg = 2.09 ± 0.2 nm indicates compact tertiary structure.

Structural Analysis

The PDDF function was derived from the SAXS intensity profile using indirect Fourier transformation, providing insights into the spatial distribution of atom pairs within the liraglutide molecule. The calculated Rg = 2.09 ± 0.2 nm is a key parameter reflecting the overall size and compactness of the peptide structure in solution.

Comparison of the DANNALAB SAXS data with synchrotron data (Biophysical Journal Volume 109, September 2015, 1202-1213) shows a high degree of similarity in the overall shape of the PDDF function and the Rg value.

Conclusion

The determination of tertiary structural parameters, such as the radius of gyration and the spatial distribution of atoms, helps assess how the liraglutide molecule folds and interacts in solution. Since the tertiary structure plays a pivotal role in the peptide's pharmaceutical function, these data are important in guiding formulation, stability studies, and regulatory approval processes for peptide-based drugs.

Laboratory SAXS instruments provide a cost-effective and accessible means to support biopharmaceutical development, offering crucial insights into the structural properties of peptide-based drugs.

Reference: Biophysical Journal Volume 109, September 2015, 1202-1213

Related Application Notes